MedTrace Logo

Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer

NCT06984250 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 315

Last updated 2025-05-22

No results posted yet for this study

Summary

Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy

Conditions

  • Early Breast Cancer
  • Ductal Breast Carcinoma In Situ

Interventions

RADIATION

Hypofractionated Radiation Therapy

Hypofractionated breast radiotherapy (HFRT) with hybrid techniques combining field-in-field intensity-modulated RT (FIF-IMRT) to the whole breast with inverse-IMRT for concomitant boost

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-06
Primary Completion
2027-02-28
Completion
2030-02-28
FDA Device
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06984250 on ClinicalTrials.gov